DSG was among the first ePRO providers to market in 1999, deploying tens of thousands of application-based devices for sponsors collecting patient reported outcomes electronically. The FDA fully embraced the date-time stamped reliability of ePRO.
Each new ePRO study meant developing new software applications dependent upon the device platform, leasing or purchasing devices with associated logistics costs and accounting for lost and broken devices, making ePRO a highly desirable yet expensive solution especially for large patient populations.
eCaseLink.Me provides a flexible approach to patient-reported data capture. eCaseLink.Me can be used alone or in combination with eCaseLink EDC software for reporting and data analysis. Designed with the patient in mind, eCaseLink-Me allows patients to personalize and change the appearance of the application to better suit preferences. It works on any browser or web-enabled device, so that patients may enter data conveniently from any wifi-enabled location – no need for unfamiliar devices.
eCaseLink.Me is a highly affordable, fully configurable ePRO solution including all required functions and advantages such as:
- Auto email and text message reminders and alerts
- Time controlled login
- Patient-configurable user-interface
- Dynamic/conditional release of questions
- Validated questionnaires and scales
- Wholly intuitive, no patient training required
- Extremely rapid start-up time
- Works on any web browser
DSG's experience and capabilities in electronic patient-reported studies since our first deployments in 1999 spans over 20 therapeutic areas and 93 countries. DSG, an industry recognized leader in data capture innovations, offers options and flexibility that are right for your next trial. Our cost-effective pricing model ensures that you receive the most appropriate solution for your study.
If you are interested in learning more about eCaseLink.Me or any of DSG's ePRO capabilities, email:firstname.lastname@example.org or call us at (484) 913-0210 x 112 for a demonstration.
Return to top